BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma

BACKGROUND: The development of rational combination therapies is key to overcome inherent treatment resistance of glioblastoma (GBM). We aim at identifying new druggable targets by disturbing GBM cells with inhibitors of bromodomain and extra-terminal motif (BET) proteins to reveal cancer-relevant v...

Descripción completa

Detalles Bibliográficos
Autores principales: Gusyatiner, Olga, Bady, Pierre, Pham, Minh D T, Lei, Yvonne, Park, Jungyeon, Daniel, Roy T, Delorenzi, Mauro, Hegi, Monika E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485441/
https://www.ncbi.nlm.nih.gov/pubmed/33987681
http://dx.doi.org/10.1093/neuonc/noab115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485441/
https://www.ncbi.nlm.nih.gov/pubmed/33987681
http://dx.doi.org/10.1093/neuonc/noab115

Ejemplares similares